DAFTAR PUSTAKA

1. WHO. *Polycystic Ovary Syndrome.*; 2023. Accessed February 16, 2025. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome

2. Harada M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. *Reprod Med Biol.* 2022;21(1). doi:10.1002/rmb2.12487

3. Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment with Emphasis on Adolescent Girls. *J Endocr Soc.* 2019;3(8):1545-1573. doi:10.1210/js.2019-00078

4. Kumar R, Minerva S, Shah R, et al. Role of genetic, environmental, and hormonal factors in the progression of PCOS: A review. *Journal of Reproductive Healthcare and Medicine.* 2022;3:3. doi:10.25259/jrhm_16_2021

5. Bulsara J, Patel P, Soni A, Acharya S. A review: Brief insight into Polycystic Ovarian syndrome. *Endocrine and Metabolic Science.* 2021;3. doi:10.1016/j.endmts.2021.100085

6. Singh S, Pal N, Shubham S, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. *J Clin Med.* 2023;12(4). doi:10.3390/jcm12041454

7. Freeman AM, Burks HR, Wild RA. Diagnostic Criteria and Epidemiology of PCOS. In: *Polycystic Ovary Syndrome: Current and Emerging Concepts.* Springer; 2022:3-11. https://link.springer.com/book/10.1007/978-3-030-92589-5

8. Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. *J Ovarian Res.* 2023;16(1). doi:10.1186/s13048-022-01091-0

9. Chiaffarino F, Cipriani S, Dalmartello M, et al. Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. *European journal of Obstetrics Gynecology and Reproductive Biology Review article.* 2022;279:159-170.

10. Carmina E. Need to Introduce the Finding of Obesity or Normal Body Weight in the Current Diagnostic Criteria and in the

Classification of PCOS. *Diagnostics*. 2022;12(10). doi:10.3390/diagnostics12102555

11. Singh S, Pal N, Shubham S, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. *J Clin Med*. 2023;12(4). doi:10.3390/jcm12041454

12. Xu XL, Deng SL, Lian ZX, Yu K. Estrogen receptors in polycystic ovary syndrome. *Cells*. 2021;10(2):1-13. doi:10.3390/cells10020459

13. Przybycień P, Gąsior-Perczak D, Placha W. Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility. *Cells*. 2022;11(16). doi:10.3390/cells11162569

14. Psilopatis I, Vrettou K, Nousiopoulou E, Palamaris K, Theocharis S. The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome. *J Clin Med*. 2023;12(8). doi:10.3390/jcm12082912

15. Shabbir S, Khurram E, Moorthi VS, Eissa YTH, Kamal MA, Butler AE. The interplay between androgens and the immune response in polycystic ovary syndrome. *J Transl Med*. 2023;21(1). doi:10.1186/s12967-023-04116-4

16. Alqahtani A, Ayesh HSK, Halawani H. PIK3CA gene mutations in solid malignancies: Association with clinicopathological parameters and prognosis. *Cancers (Basel)*. 2020;12(1). doi:10.3390/cancers 12010093

17. Permatasari HK, Nurkolis F, Hardinsyah H, et al. Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels. *Front Nutr*. 2022;9. doi:10.3389/fnut.2022.939073

18. Nurkolis F, Purnomo AF, Alisaputra D, et al. In silico and in vitro studies reveal a synergistic potential source of novel anti-ageing from two Indonesian green algae. *J Funct Foods*. 2023;104. doi:10.1016/j.jff.2023.105555

19. Nurkolis F, Hardinsyah H, Taslim NA, et al. Effect of Sea grapes-Antioxidants Extract on Lipid Profile and PGC-1α Levels in Obese Men: 4 Weeks Randomized-Double Blind Controlled Trial. *Proceedings of the Nutrition Society*. 2022;81(OCE2). doi:10.1017/s0029665122000866

20. Mayulu N, Gunawan W Ben, Park MN, et al. Sulfated Polysaccharide from Caulerpa racemosa Attenuates the Obesity-Induced Cardiometabolic Syndrome via Regulating the PRMT1-DDAH-ADMA with mTOR-SIRT1-AMPK Pathways and Gut Microbiota Modulation. *Antioxidants*. 2023;12(8). doi:10.3390/antiox12081555

21. Noor F, Asif M, Ashfaq UA, Qasim M, Tahir Ul Qamar M. Machine learning for synergistic network pharmacology: a comprehensive overview. *Brief Bioinform*. 2023;24(3). doi:10.1093/bib/bbad120

22. Mokashi AA, Bhatia N, Mokashi A, Nathore N, Nathore A. International Journal of Medical Science and Clinical Research Studies Network Pharmacology: An Emphasis on Traditional Chinese Medicines and Its Adaptability for Ayurveda Medicines in India. Published online 2022. doi:10.47191/ijmscrs/v2

23. Dong J, Rees DA. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. *BMJ Medicine*. 2023;2(1):e000548. doi:10.1136/bmjmed-2023-000548

24. Chiaffarino F, Cipriani S, Dalmartello M, et al. *Prevalence of Polycystic Ovary Syndrome in European Countries and USA: A Systematic Review and Meta-Analysis. European Journal of Obstetrics Gynecology and Reproductive Biology*. Vol 279.; 2022. Accessed February 17, 2025. https://www.ejog.org/article/S0301-2115(22)00568-1/abstract

25. Sobti S, Dewan R, Ranga S. Metabolic syndrome and insulin resistance in PCOS phenotypes. *Int J Reprod Contracept Obstet Gynecol*. 2017;6(11):5067. doi:10.18203/2320-1770.ijrcog20175027

26. Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, et al. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study. *Front Endocrinol (Lausanne)*. 2022;13. doi:10.3389/fendo.2022.825528

27. Elasam AN, Ahmed MA, Ahmed ABA, et al. The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. *BMC Womens Health*. 2022;22(1). doi:10.1186/s12905-022-01762-6

28. Barber TM FS. Chapter 27 Genetic and Environmental Factors in the Etiology of Polycystic Ovary Syndrome. In: *Book of The Ovary*. ;

2019. Accessed February 18, 2025. https://doi.org/10.1016/B978-0-12-813209-8.00027-3Get rights and content

29. Dapas M, Dunaif A. Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. *Endocr Rev*. 2022;43(6):927-965. doi:10.1210/endrev/bnac001

30. Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives. *Application of Clinical Genetics*. 2019;12:249-260. doi:10.2147/TACG.S200341

31. Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. *Eur J Obstet Gynecol Reprod Biol X*. 2019;3. doi:10.1016/j.eurox.2019.100060

32. Combs JC, Hill MJ, Decherney AH. Polycystic Ovarian Syndrome Genetics and Epigenetics. *Clin Obstet Gynecol*. 2021;64(1):20-25. doi:10.1097/GRF.0000000000000581

33. Azziz R. Polycystic Ovary Syndrome. *Obstetrics & Gynecology 132(2)*. 2018;132(2):p 321-336. doi:doi:10.1097/AOG.000000000000 2698

34. Unluhizarci K, Karaca Z, Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders. *World J Diabetes*. 2021;12(5):616-629. doi:10.4239/wjd.v12.i5.616

35. Xu Y, Qiao J. Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature. *J Healthc Eng*. 2022;2022. doi:10.1155/2022/9240569

36. Kamenov Z, Gateva A. Inositols in PCOS. *Molecules*. 2020;25(23). doi:10.3390/molecules25235566

37. Fahs D, Salloum D, Nasrallah M, Ghazeeri G. Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis. *Diagnostics*. 2023;13(9). doi:10.3390/diagnostics13091559

38. Khatun M, Lundin K, Naillat F, et al. Induced Pluripotent Stem Cells as a Possible Approach for Exploring the Pathophysiology of Polycystic Ovary Syndrome (PCOS). *Stem Cell Rev Rep*. 2024;20(1):67-87. doi:10.1007/s12015-023-10627-w

39. Fahs D, Salloum D, Nasrallah M, Ghazeeri G. Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis. *Diagnostics*. 2023;13(9). doi:10.3390/diagnostics13091559

40. Pea J, Bryan J, Wan C, et al. Ultrasonographic criteria in the diagnosis of polycystic ovary syndrome: a systematic review and diagnostic meta-analysis. *Hum Reprod Update*. 2024;30(1):109-130. doi:10.1093/humupd/dmad027

41. Tong C, Wu Y, Zhang L, Yu Y. Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway. *Front Endocrinol (Lausanne)*. 2022;13. doi:10.3389/fendo.2022.1091147

42. Bahri Khomami M, Joham AE, Boyle JA, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity—A systematic review, meta-analysis, and meta-regression. *Obesity Reviews*. 2019;20(5):659-674. doi:10.1111/obr.12829

43. Dissanayake IH, Bandaranayake U, Keerthirathna LR, et al. Integration of in vitro and in-silico analysis of Caulerpa racemosa against antioxidant, antidiabetic, and anticancer activities. *Sci Rep*. 2022;12(1). doi:10.1038/s41598-022-24021-y

44. Lau V, Nurkolis F, Park MN, et al. Green Seaweed Caulerpa racemosa as a Novel Non-Small Cell Lung Cancer Inhibitor in Overcoming Tyrosine Kinase Inhibitor Resistance: An Analysis Employing Network Pharmacology, Molecular Docking, and In Vitro Research. *Mar Drugs*. 2024;22(6). doi:10.3390/md22060272

45. Tjitrosoepomo G. *Taksonomi Tumbuhan (Schizophyta, Thallophyta, Bryophyta, Pteridophyta)*. 10th ed. Gadjah Mada University Press; 2014.

46. Ferial EW SM. *Fikologi*. (Amalia Safitri, ed.). Penerbit Erlangga; 2016.

47. Gambar Caulerpa racemosa. https://seaweednetwork.id/budidaya-anggur-laut-caulerpa-racemosa-melalui-media-tanam-rigid-quadrant-nets-berbahan-bambu

48. Nurkolis F, Taslim NA, Subali D, et al. Dietary Supplementation of Caulerpa racemosa Ameliorates Cardiometabolic Syndrome via Regulation of PRMT-1/DDAH/ADMA Pathway and Gut Microbiome in Mice. *Nutrients*. 2023;15(4). doi:10.3390/nu15040909

49. Darmawan M FNSIH. *Caulerpa: Ecology, Nutraceutical and Pharmaceutical Potential. In: Marine Niche: Applications in*

Pharmaceutical Sciences. Springer; 2020. Accessed February 17, 2025. https://link.springer.com/chapter/10.1007/978-981-15-5017-1_17

50. Mert-Ozupek N, Calibasi-Kocal G, Olgun N, Basbinar Y, Cavas L, Ellidokuz H. In-silico molecular interactions among the secondary metabolites of Caulerpa spp. and colorectal cancer targets. *Front Chem*. 2022;10. doi:10.3389/fchem.2022.1046313

51. De Souza ÉT, De Lira DP, De Queiroz AC, et al. The antinociceptive and anti-inflammatory activities of caulerpin, a bisindole alkaloid isolated from seaweeds of the genus Caulerpa. *Mar Drugs*. 2009;7(4):689-704. doi:10.3390/md7040689

52. Agena R, Cortés-Sánchez ADJ, Hernández-Sánchez H, et al. Pro-Apoptotic Activity and Cell Cycle Arrest of Caulerpa sertularioides against SKLU-1 Cancer Cell in 2D and 3D Cultures. *Molecules*. 2023;28(11). doi:10.3390/molecules28114361

53. Cuomo P, Medaglia C, Allocca I, et al. Caulerpin mitigates helicobacter pylori-induced inflammation via formyl peptide receptors. *Int J Mol Sci*. 2021;22(23). doi:10.3390/ijms222313154

54. Abílio GMF, Camilo CJ, Coutinho HDM, et al. Cytotoxic and Anti-HSV-1 Effects of Caulerpin Derivatives. *Molecules*. 2024;29(16). doi:10.3390/molecules29163859

55. Pangestuti R, Haq M, Rahmadi P, Chun BS. Nutritional value and biofunctionalities of two edible green seaweeds (Ulva lactuca and caulerpa racemosa) from indonesia by subcritical water hydrolysis. *Mar Drugs*. 2021;19(10). doi:10.3390/md19100578

56. Magdugo RP, Terme N, Lang M, et al. An analysis of the nutritional and health values of Caulerpa racemosa (Forsskål) and Ulva fasciata (Delile)—Two chlorophyta collected from the Philippines. *Molecules*. 2020;25(12). doi:10.3390/molecules25122901

57. Aroyehun AQB, Razak SA, Palaniveloo K, et al. Bioprospecting cultivated tropical green algae, caulerpa racemosa: a perspective on nutritional properties, antioxidative capacity and anti-diabetic potential. *Foods*. 2020;9(9). doi:10.3390/foods9091313

58. Mert-Ozupek N, Calibasi-Kocal G, Olgun N, Basbinar Y, Cavas L, Ellidokuz H. In-silico molecular interactions among the secondary metabolites of Caulerpa spp. and colorectal cancer targets. *Front Chem*. 2022;10. doi:10.3389/fchem.2022.1046313

59. Magdugo RP, Terme N, Lang M, et al. An analysis of the nutritional and health values of Caulerpa racemosa (Forsskål) and Ulva fasciata (Delile)—Two chlorophyta collected from the Philippines. *Molecules*. 2020;25(12). doi:10.3390/molecules25122901

60. Mayulu N, Gunawan W Ben, Park MN, et al. Sulfated Polysaccharide from Caulerpa racemosa Attenuates the Obesity-Induced Cardiometabolic Syndrome via Regulating the PRMT1-DDAH-ADMA with mTOR-SIRT1-AMPK Pathways and Gut Microbiota Modulation. *Antioxidants*. 2023;12(8). doi:10.3390/antiox12081555

61. Sanger G, Wonggo D, Taher N, et al. Green seaweed Caulerpa racemosa - Chemical constituents, cytotoxicity in breast cancer cells and molecular docking simulation. *J Agric Food Res*. 2023;12. doi:10.1016/j.jafr.2023.100621

62. Permatasari HK, Barbara Ulfa EN, Adyana Daud VP, Sulistomo HW, Nurkolis F. Caulerpa racemosa extract inhibits HeLa cancer cells migration by altering expression of epithelial-mesenchymal transition proteins. *Front Chem*. 2022;10. doi:10.3389/fchem.2022.1052238

63. Yap WF, Tay V, Tan SH, Yow YY, Chew J. Decoding antioxidant and antibacterial potentials of Malaysian green seaweeds: Caulerpa racemosa and caulerpa lentillifera. *Antibiotics*. 2019;8(3). doi:10.3390/antibiotics8030152

64. Padilha EC, Serafim RB, Sarmiento DYR, Santos CF, Santos CBR, Silva CHTP. New PPARα/γ/δ optimal activator rationally designed by computational methods. *J Braz Chem Soc*. 2016;27(9):1636-1647. doi:10.5935/0103-5053.20160043

65. Ballav S, Biswas B, Sahu VK, Ranjan A, Basu S. PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer. *Cells*. 2022;11(20). doi:10.3390/cells11203215

66. Vitti M, Di Emidio G, Di Carlo M, et al. Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility. *PPAR Res*. 2016;2016. doi:10.1155/2016/4612306

67. Mir R, Tayeb FJ, Barnawi J, et al. Biochemical Characterization and Molecular Determination of Estrogen Receptor-α (ESR1 PvuII-rs2234693 T>C) and MiRNA-146a (rs2910164 C>G) Polymorphic Gene Variations and Their Association with the Risk of Polycystic Ovary Syndrome. *Int J Environ Res Public Health*. 2022;19(5). doi:10.3390/ijerph19053114

68. McAllister JM, Legro RS, Modi BP, Strauss JF. Functional genomics of PCOS: From GWAS to molecular mechanisms. *Trends in Endocrinology and Metabolism*. 2015;26(3):118-124. doi:10.1097/01.ogx.0000471341.33429.55

69. Huang WY, Sun PM. Estrogen receptor-associated receptor α and peroxisome proliferator-activated receptor γ in metabolism and disease (Review). *Mol Med Rep*. 2021;23(2). doi:10.3892/mmr.2020.11795

70. Shaaban Z, Khoradmehr A, Amiri-Yekta A, Nowzari F, Jafarzadeh Shirazi MR, Tamadon A. Pathophysiologic Mechanisms of Insulin Secretion and Signaling-Related Genes in Etiology of Polycystic Ovary Syndrome. *Genet Res (Camb)*. 2021;2021. doi:10.1155/2021/7781823

71. Vilariño-García T, Guadix P, Dorado-Silva M, Sánchez-Martín P, Pérez-Pérez A, Sánchez-Margalet V. Decreased Expression of Sam68 Is Associated with Insulin Resistance in Granulosa Cells from PCOS Patients. *Cells*. 2022;11(18). doi:10.3390/cells11182821

72. Hao M, Yuan F, Jin C, et al. Overexpression of Lnk in the Ovaries Is Involved in Insulin Resistance in Women With Polycystic Ovary Syndrome. *Endocrinology*. 2016;157(10):3709-3718. doi:10.1210/en.2016

73. Chen H, Deng C, Meng Z, Meng S. Effects of TCM on polycystic ovary syndrome and its cellular endocrine mechanism. *Front Endocrinol (Lausanne)*. 2023;14. doi:10.3389/fendo.2023.956772

74. Seo HY, Lee SH, Lee JH, Lee JH, Jang BK, Kim MK. Kahweol induces apoptosis in hepatocellular carcinoma cells by inhibiting the Src/mTOR/STAT3 signaling pathway. *Int J Mol Sci*. 2021;22(19). doi:10.3390/ijms221910509

75. Zheng W, Guo Y, Zhang G, et al. Peptide encoded by lncRNA BVES-AS1 promotes cell viability, migration, and invasion in colorectal cancer cells via the SRC/ mTOR signaling pathway. *PLoS One*. 2023;18(6 June). doi:10.1371/journal.pone.0287133

76. Bolós V, Gasent JM, López-Tarruella S, Grande E. *OncoTargets and Therapy The Dual Kinase Complex FAK-Src as a Promising Therapeutic Target in Cancer*.; 2010. www.dovepress.com

77. Pal R, Palmieri M, Chaudhury A, et al. Src regulates amino acid-mediated mTORC1 activation by disrupting GATOR1-Rag GTPase

interaction. *Nat Commun*. 2018;9(1). doi:10.1038/s41467-018-06844-4

78. Alqahtani A, Ayesh HSK, Halawani H. PIK3CA gene mutations in solid malignancies: Association with clinicopathological parameters and prognosis. *Cancers (Basel)*. 2020;12(1). doi:10.3390/cancers 12010093

79. Han J, Shi J, Jiang M, et al. Clinical Characteristics and Prognostic Values of PIK3CA Mutation in Colorectal Cancer Patients. *J Cancer Sci Clin Ther*. 2022;06(01). doi:10.26502/jcsct.5079149

80. Liu J, Wu DC, Qu LH, Liao HQ, Li MX. The role of mTOR in ovarian Neoplasms, polycystic ovary syndrome, and ovarian aging. *Clinical Anatomy*. 2018;31(6):891-898. doi:10.1002/ca.23211

81. Guo Z, Yu Q. Role of mTOR Signaling in Female Reproduction. *Front Endocrinol (Lausanne)*. 2019;10. doi:10.3389/fendo.2019.00692

82. Liu J, Wu DC, Qu LH, Liao HQ, Li MX. The role of mTOR in ovarian Neoplasms, polycystic ovary syndrome, and ovarian aging. *Clinical Anatomy*. 2018;31(6):891-898. doi:10.1002/ca.23211

83. Gedaly R. mTOR Signaling in Regulatory T Cell Differentiation and Expansion. *SOJ Immunol*. 2015;3(1). doi:10.15226/soji/3/1/00122

84. Surabhi S, Singh B. Computer Aided Drug Desain: An Overview. *Journal of Drug Delivery and Therapeutics*. 2018;8(5):504-509. doi:10.22270/jddt.v8i5.1894

85. Makar S, Saha T, Swetha R, Gutti G, Kumar A, Singh SK. *Rational Approaches of Drug Design for the Development of Selective Estrogen Receptor Modulators (SERMs), Implicated in Breast Cancer*.; 2019.

86. Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A Guide to In Silico Drug Design. *Pharmaceutics*. 2023;15(1). doi:10.3390/pharmaceutics15010049

87. Khaerunnisa S SAR. *Penelitian In Silico Untuk Pemula*. Penerbit Airlangga University Press; 2020.

88. Wicaksono D, Taslim NA, Lau V, et al. Elucidation of anti-human melanoma and anti-aging mechanisms of compounds from green

seaweed Caulerpa racemosa. *Sci Rep*. 2024;14(1):27534. doi:10.1038/s41598-024-78464-6

89. Nurkolis F, Taslim NA, Qhabibi FR, et al. Ulvophyte Green Algae Caulerpa lentillifera: Metabolites Profile and Antioxidant, Anticancer, Anti-Obesity, and In Vitro Cytotoxicity Properties. *Molecules*. 2023;28(3). doi:10.3390/molecules28031365

90. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep*. 2017;7. doi:10.1038/srep42717

91. Xijin Ge S, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. doi:10.5281/zenodo.1451847

92. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003;13(11):2498-2504. doi:10.1101/gr.1239303

93. Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. *Nucleic Acids Res*. 2022;50(W1):W159-W164. doi:10.1093/nar/gkac394

94. Arneth B, Arneth R, Shams M. Metabolomics of type 1 and type 2 diabetes. *Int J Mol Sci*. 2019;20(10). doi:10.3390/ijms20102467

95. Yang P, Liu DQ, Liang TJ, et al. Bioactive constituents from the green alga Caulerpa racemosa rights and content. doi:10.1016/j.bmc.2014. 11.031Get

96. Heinrich M, Mah J, Amirkia V. Alkaloids used as medicines: Structural phytochemistry meets biodiversity—An update and forward look. *Molecules*. 2021;26(7). doi:10.3390/molecules26071836

97. Omar F, Tareq AM, Alqahtani AM, et al. Plant-based indole alkaloids: A comprehensive overview from a pharmacological perspective. *Molecules*. 2021;26(8). doi:10.3390/molecules26082297

98. Chen L, Pang Y, Luo Y, Cheng X, Lv B, Li C. Separation and purification of plant terpenoids from biotransformation. *Eng Life Sci*. 2021;21(11):724-738. doi:10.1002/elsc.202100014

99. Parekh SS, Parmar GR, Kanojiya D, Baile SB, Trivedi R, Bhatt F. Unlocking the Therapeutic Potential of Terpenoids: A Roadmap for Future Medicine. *Pharmacognosy Res*. 2024;16(4):698-705. doi:10.5530/pres.16.4.81

100. Yang W, Chen X, Li Y, Guo S, Wang Z, Yu X. Advances in Pharmacological Activities of Terpenoids. *Nat Prod Commun*. 2020;15(3). doi:10.1177/1934578X20903555

101. Guo J, Huang M, Hou S, et al. Therapeutic Potential of Terpenoids in Cancer Treatment: Targeting Mitochondrial Pathways. *Cancer Rep*. 2024;7(9). doi:10.1002/cnr2.70006

102. Zou P, Wang L, Liu F, Yan Z, Chen X. Effect of interfering TOR signaling pathway on the biosynthesis of terpenoids in Salvia miltiorrhiza Bge. *Plant Signal Behav*. 2023;18(1). doi:10.1080/15592324.2023.2199644

103. Rowett AC, Heard DM, Koria P, Dean AC, Sweeting SG, Lennox AJJ. 200 Years of The Haloform Reaction: Methods and Applications. *Chemistry – A European Journal*. 2024;30(71). doi:10.1002/chem.202403045

104. Liu Q, Mao SC, Zhang HY, et al. Racemosins A and B, two novel bisindole alkaloids from the green alga Caulerpa racemosa Author links open overlay panel Ding. *Fitoterapia*. 2013;91:15-20. doi:10.1016/j.fitote.2013.08.014Get

105. Zhou J, Zhong L. Applications of liquid chromatography-mass spectrometry based metabolomics in predictive and personalized medicine. *Front Mol Biosci*. 2022;9. doi:10.3389/fmolb.2022.1049016

106. Pathak S, Banerjee A. *Plant Derived Bioactive Compounds in Human Health and Disease*. CRC Press; 2024. doi:10.1201/9781003486237

107. Jiao X, Chen W, Zhang J, et al. Variant alleles of the ESR1, PPARG, HMGA2, and MTHFR genes are associated with polycystic ovary syndrome risk in a Chinese population: A case-control study. *Front Endocrinol (Lausanne)*. 2018;9(AUG). doi:10.3389/fendo.2018.00504

108. Shi CY, Xu JJ, Li C, Yu J Le, Wu YT, Huang HF. A PPARG Splice Variant in Granulosa Cells Is Associated with Polycystic Ovary Syndrome. *J Clin Med*. 2022;11(24). doi:10.3390/jcm11247285

109. Dabravolski SA, Nikiforov NG, Eid AH, et al. Molecular Sciences Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome. *J Mol Sci*. Published online 2021:22. doi:10.3390/ijms

110. Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). *Life Sci*. 2019;228:167-175. doi:10.1016/j.lfs.2019.04.046

111. Kuswari M, Nurkolis F, Mayulu N, et al. Sea grapes extract improves blood glucose, total cholesterol, and PGC-1α in rats fed on cholesterol- and fat-enriched diet. *F1000Res*. 2021;10:718. doi:10.12688/f1000research.54952.1

112. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. *Int J Mol Sci*. 2022;23(8). doi:10.3390/ijms23084110

113. Makker A, Goel MM, Das V, Agarwal A. PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: An update. *Gynecological Endocrinology*. 2012;28(3):175-181. doi:10.3109/09513590.2011.583955

LAMPIRAN

Lampiran 1. Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari .MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 5/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 6 Januari 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25010008	No Sponsor	
Peneliti Utama	**dr. Aryanti, M.Kes, Sp.GK(K), FISQua, AIFO-K**	Sponsor	
Judul Peneliti	Studi Farmakoinformatika Anggur Laut (Caulerpa racemosa) sebagai Modalitas Novel Terapi pada Polycystic Ovary Syndrome (PCOS) : Kajian Uji Metabolomik dan In Silico melalui Network Pharmacology dan Molecular Docking		
No Versi Protokol	1	Tanggal Versi	**2 Januari 2025**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Universitas Brawijaya Malang dan Universitas Islam Negeri Sunan Kalijaga Yogyakarta		
Jenis Review	[X] Exempted [ ] Expedited [ ] Fullboard Tanggal	Masa Berlaku 6 Januari **2025** sampai 6 Januari 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	**Prof. dr. Muh Nasrum Massi,PhD,SpMK, Subsp. Bakt(K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	**dr. Firdaus Hamid, PhD, SpMK(K)**	Tanda tangan	

Kewajiban Peneliti Utama

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Alur Kerja Studi Insiliko



Lampiran 3. Hasil Kromatogram HPLC-ESI-HRMS/MS Senyawa Bioaktif *Caulerpa racemosa*



Lampiran 4. Hasil Penambatan Molekuler

ESR1_Caulerpin



ESR1_Caulersin



ESR1_Caulerpenyne



ESR1_Racemosin



ESR1_Simvastatin



ESR1_Orlistat




PPARγ_Caulerpin
PPARγ_Caulersin
PPARγ_Caulerpenyne
PPARγ_Racemosin
PPARγ_Simvastatin
PPARγ_Orlistat

Src_Caulerpin



Src_Caulersin



Src_Caulerpenyne



Src_Racemosin



Src_Simvastatin

Src_Orlistat




PIK3CA_Caulerpin
PIK3CA_Caulersin
PIK3CA_Caulerpenyne
PIK3CA_Racemosin
PIK3CA_Simvastatin
PIK3CA_Orlistat


mTOR_Caulerpin
PRO B:1537
THR B:1540
ARG B:1538
mTOR _Caulersin
ARG B:1538
PRO B:1537
mTOR_Caulerpenyne
ARG B:1538
mTOR _Racemosin
ARG B:1538
PRO B:1537
mTOR_Simvastatin
THR B:1540
PRO B:1537
ARG B:1538
mTOR_Orlistat

Lampiran 5. Alat Laboratrorium dan Hasil Ekstraksi

Alat Kromatografi

Hasil Ekstraksi *Caulerpa racemosa*